Ironwood Pharmaceuticals (IRWD) Non-Current Assets (2010 - 2026)
Ironwood Pharmaceuticals (IRWD) posted Non-Current Assets of $102.3 million for Q1 2026, down 16.66% sequentially from $122.7 million in Q4 2025, and down 38.62% YoY from $166.6 million in Q1 2025.
Ironwood Pharmaceuticals (IRWD) Non-Current Assets (2010 - 2026) Analysis & Trends
Ironwood Pharmaceuticals has reported Non-Current Assets for 17 years, with the latest figure at $102.3 million in Q1 2026.
- Quarterly Non-Current Assets fell 38.62% year-over-year to $102.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $498.4 million (down 34.72% YoY) and the FY2025 annual result came in at $122.7 million, down 27.18% from the prior year.
- Non-Current Assets eased to $102.3 million in Q1 2026 per IRWD's latest filing, from $122.7 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $373.3 million in Q1 2022 and troughed at $102.3 million in Q1 2026.
- A 5-year average of $233.4 million and a median of $230.6 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 510.95% in 2022, then slumped 42.05% in 2025.
- Over 5 years, Non-Current Assets stood at $319.9 million in 2022, then slipped by 25.67% to $237.8 million in 2023, then fell by 29.12% to $168.5 million in 2024, then slipped by 27.18% to $122.7 million in 2025, then dropped by 16.66% to $102.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $102.3 million, $122.7 million, and $122.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Ironwood Pharmaceuticals | 679.81 Mn | 600.69 Mn | - | 85.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 85.93 Mn |
| Mar 31, 2026 | 102.27 Mn |
| Dec 31, 2025 | 122.72 Mn |
| Sep 30, 2025 | 122.22 Mn |
| Jun 30, 2025 | 151.19 Mn |
| Mar 31, 2025 | 166.63 Mn |
| Dec 31, 2024 | 168.54 Mn |
| Sep 30, 2024 | 210.92 Mn |
| Jun 30, 2024 | 217.44 Mn |
| Mar 31, 2024 | 230.65 Mn |
| Dec 31, 2023 | 237.79 Mn |
| Sep 30, 2023 | 270.45 Mn |
| Jun 30, 2023 | 285.62 Mn |
| Mar 31, 2023 | 288.90 Mn |
| Dec 31, 2022 | 319.89 Mn |
| Sep 30, 2022 | 341.35 Mn |
| Jun 30, 2022 | 357.86 Mn |
| Mar 31, 2022 | 373.28 Mn |
| Dec 31, 2021 | 381.70 Mn |
| Sep 30, 2021 | 384.00 Mn |